Chile researchers said they have developed the first vaccine against respiratory syncytial virus (RSV) that usually results in respiratory and tract infections in children. The team stated after clinical trials were done, the vaccine will be released into the market in four to five years.
Notably, RSV kills thousands of babies across the world each year. According to the Mayo Clinic in the United States, the Virus is common and most children have been infected with it by age two.
In climates that of Chile, there are annual epidemics of the virus in winter. The vaccine was developed after ten years of work by a team led by Dr. Alexis Kalergis at the Millennium Institute on Immunology and Immunotherapy.
Kalergis said the virus is very harmful and costly for Chilean society and majority of countries. He added the vaccine is successful in tests with animals and the team is ready for clinical trials on people. The vaccine would be released in four to five years provided the results are favorable.